ISOCHEM S.A.S

What ISOCHEM S.A.S does

ISOCHEM S.A.S, operating under the trade name PMC Isochem, is a France-based private pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Vert-le-Petit, founded in 1974. The company manufactures and markets intermediates, generic active pharmaceutical ingredients (APIs), excipients, and polymer-based drug delivery materials for pharmaceutical companies worldwide. Its technology platform centers on specialized chemical synthesis capabilities including phosgenation, hydrogenation, halogenation, cryogenic chemistry, and distillation, all operated under cGMP standards. Catalogue products include Vitamin E TPGS and polyamino acid-based drug delivery materials, NCA-UNCA compounds, cGMP intermediates, and anti-scratch varnishes, while custom services span end-to-end development and manufacturing for client drug pipelines.

The company generates revenue through project-based custom development and manufacturing contracts (CDMO services), direct sales of catalogue intermediates and APIs to pharmaceutical manufacturers, and contract research (CRO) services including analytical development and drug delivery/nanoformulation. Pricing is not publicly disclosed and is quote-based per project, consistent with B2B pharma CDMO norms. Go-to-market relies on direct enterprise field sales supported by an inquiry/application process on the corporate website, attendance at industry events such as DCAT Week (New York) and CHEM BIO Symposium (France), and downloadable technical resources. In January 2026 the company expanded into CRO activities specializing in analytical development and nanoformulation, and it previously broadened its footprint via the 2012 acquisition of Wychem Ltd.

Name

ISOCHEM S.A.S

Legal name

ISOCHEM S.A.S

Website

https://isochem.eu

Company type

Private

Founded year

1974

Operating status

Operating

Headcount range

251–500 employees

Short description

ISOCHEM S.A.S (PMC Isochem) is a France-based pharmaceutical CDMO founded in 1974 that manufactures cGMP intermediates, generic APIs, excipients, and drug delivery polymers for pharmaceutical companies globally using specialized chemistry capabilities.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Pharmaceutical CDMO services
• CGMP pharmaceutical intermediates
• Active pharmaceutical ingredients
• Drug delivery materials
• Custom chemical synthesis

Headquarters

HQ city

Vert-le-petit

HQ country

France

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Custom Development and Manufacturing (CDMO) Services: Provides custom development and manufacturing services to pharmaceutical companies for intermediates, APIs, excipients, and polymers. Revenue is generated through project-based contracts with pharmaceutical clients for drug development and manufacturing.
2. Catalogue Products: Sale of catalogue products including cGMP Intermediates, Generic APIs, Drug delivery materials (Vitamin E TPGS, Polyamino acids), NCA-UNCA compounds, and Anti-scratch varnishes. Products are sold to pharmaceutical manufacturers.
3. Contract Research Services: CRO services including analytical services and drug delivery services for pharmaceutical research and development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

ISOCHEM S.A.S (operating as PMC Isochem) is a France-based Contract Development and Manufacturing Organization (CDMO) for the global pharmaceutical industry. It manufactures and markets cGMP intermediates, generic Active Pharmaceutical Ingredients (APIs), excipients, and specialty polymers for drug delivery, and provides custom chemical synthesis, contract research (CRO) analytical services, and drug delivery/nanoformulation services.

Product overview

PMC Isochem operates as a Custom Development & Manufacturing Organization (CDMO) offering a portfolio of catalogue products and contract services. The product portfolio includes cGMP Intermediates, Generic Active Pharmaceutical Ingredients (APIs), Excipients, and Polymers for drug delivery solutions. Key drug delivery materials include Vitamin E TPGS and Polyamino acids. The company also offers specialty products such as NCA-UNCA compounds and anti-scratch varnishes. Services include custom development and manufacturing, research & development, quality assurance & regulatory support, and newly launched CRO services specializing in analytical development and nanoformulation.

Differentiator

Problem solved

Functional benefit

Products and services

• Vitamin E TPGS Vitamin E TPGS (d-alpha-tocopheryl polyethylene glycol 1000 succinate) is a proprietary drug delivery material sold as an excipient for pharmaceutical formulations.
• Polyamino acids Polymer-based drug delivery materials (polyamino acids) for pharmaceutical applications, offered as catalogue products.
• Generic APIs Generic Active Pharmaceutical Ingredients manufactured and sold as catalogue products to pharmaceutical companies.
• cGMP Intermediates cGMP-compliant intermediates manufactured for pharmaceutical applications and sold as catalogue products.
• NCA - UNCA NCA (N-Carboxyanhydride) and UNCA (Urethane N-Carboxyanhydride) chemical compounds offered as specialty catalogue products.
• Anti-scratch varnishes Specialty anti-scratch varnish products sold as catalogue offerings.
• Custom Development and Manufacturing (CDMO) Project-based custom development and manufacturing services for pharmaceutical intermediates and APIs under cGMP.
• Research & Development Research and development services supporting pharmaceutical development and process optimization.
• CRO Analytical Services Contract research analytical services for pharmaceutical analysis, formally launched as part of the company's CRO offering expansion.
• CRO Drug Delivery Services Contract research drug delivery services including nanoformulation, formally launched as part of the company's CRO offering expansion.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Siegfried Holding: Siegfried is a Swiss-headquartered pharmaceutical CDMO focused on small-molecule APIs and finished drug products. Overlaps directly with PMC Isochem's CDMO scope and serves the same pharmaceutical customer base, but at significantly larger scale.
• WuXi STA (WuXi AppTec): WuXi STA is a leading global small-molecule API and intermediates CDMO in China with a broad service portfolio. Competes with PMC Isochem for the same pharmaceutical customers, particularly those seeking custom synthesis at scale.
• Lonza Group: Lonza is the world's largest pharmaceutical CDMO with comprehensive small-molecule API, intermediate, and drug product services. Comparable to PMC Isochem in offering CDMO services, but operates at vastly greater scale with a global multi-site footprint.
• Johnson Matthey (Health sector): Johnson Matthey's Health division offers pharmaceutical API and fine chemicals CDMO services, including complex chemistry. Comparable to PMC Isochem's complex synthesis and intermediates focus, but as part of a much larger diversified group.

Direct peers

• Novasep: Novasep is a French-headquartered CDMO specializing in complex small-molecule APIs, purification, and chromatography services. Comparable to PMC Isochem by French base, CDMO focus, and specialization in complex chemistry.
• Fareva: Fareva operates pharmaceutical CDMO manufacturing facilities in France and Europe, providing APIs, intermediates, and finished dosage forms. Closely comparable business model and French/European manufacturing footprint to PMC Isochem.
• Cambrex (acquired by Permira): Cambrex is a US/EU-based small-molecule API and intermediates CDMO with specialized chemistry capabilities. Directly comparable to PMC Isochem in service offering, customer base, and project-based CDMO model.
• SEQENS (formerly Novacap): SEQENS is a French-based pharmaceutical CDMO and specialty chemicals manufacturer offering custom synthesis, APIs, intermediates, and excipients. Directly comparable to PMC Isochem by geography (France), scale, and service portfolio across CDMO and pharmaceutical ingredients.

Emerging players

• PolyPeptide Group: PolyPeptide is a specialty CDMO focused on peptides and related complex chemistries. Comparable to PMC Isochem in serving pharma customers with custom synthesis, though specializing in a different molecule class.
• Eurofins CDMO (formerly Amatsigroup): Eurofins' CDMO arm (built on Amatsigroup) offers French-based pharmaceutical development and manufacturing services including analytical support. Comparable to PMC Isochem's newly launched CRO analytical and CDMO services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/28151279

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ISOCHEM S.A.S